1 / 16

MOAB0104

Reinforcement of adherence and switch to third-line in HIV-infected adults who fail second-line ART Thilao study (ANRS 12269), West Africa. MOAB0104.

nayers
Download Presentation

MOAB0104

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reinforcement of adherence and switch to third-line in HIV-infected adults who fail second-line ARTThilao study (ANRS 12269), West Africa MOAB0104 Raoul Moh, A. Benalycherif, D. Gabillard, ML. Chaix, C. Danel, L.Slama, C. Michon, PM. Girard, C. Toure-Kane, T. Toni, E. Bissagnéné, J. Drabo, M. Seydi, D. Minta, A. Sawadogo, X. Anglaret, S. Eholié, R. Landman 1 ANRS research site in Côte d’Ivoire

  2. Conflict of Interest “No conflicts of interest to declare”. 2

  3. Background In sub-Saharan Africa: • ART regimen sequencing is based on WHO guidelines: • NNRTI-based (1st line), PI (LPVr or ATVr)-based (2nd line), DRVr + INSTI-based (3rd line). • Increasing access to: • Second-line antiretroviral drugs • Viral load testing • Very low access to: • Third-line antiretroviral drugs • Genotypic resistance testing  Need for strategies that help physicians to decide when to stwich to third-line ART • « Not too early » (unjustified switch, patients with high GSS) • « Not too late » (risk of resistance accumulation) 3

  4. Thilao ANRS 12269 : Methods • Design: Pilot study. First inclusion: March 2013. Last visit: Aug 2016 • Settings: Burkina-Faso, Côte d’Ivoire, Mali, Senegal • Inclusion criteria: • Adults >18 years • History of: • 1st-line NNRTI-based regimen • Switch to 2nd-line PI-based ART for virological failure • More than 6 months on 2nd-line PI-based ART (LPV/r or ATV/r) • Confirmed plasma HIV-RNA >1000 copies/ml • Signed informed consent 4

  5. Thilao ANRS 12269 : Design Month-4 Decision Month-16 Outcomes Day-0 Inclusion Continue 2nd-line Continue 2nd-line Adherence reinforcement Switch to 3rd-line (2NRTI+darunavir 600 BID/r+raltegravir 400 BID) Inclusion criteria: VL >1000 copies/ml Month-4 Decision criteria: VL <400 copies/ml or >2 log decrease : Continue VL ≥ 400 copies/ml or < 2 log decrease : Switch Month-16 Outcomes: 1ary: Virol. success: <50 copies/ml 2ary: - Mortality • Resistance • Tolerance 5

  6. Thilao ANRS 12269 : Design Day-0 Inclusion Month-4 Decision Month-16 Outcomes Continue 2nd-line Continue 2nd-line Adherence reinforcement Switch to 3rd-line (2NRTI+darunavir 600 BID/r+raltegravir 400 BID) Adherencereinforcement = • Therapeuticeducation sessions (all patients) • + measureschosen by each patient among the followingones : Involvement of a relative, pillorganizer, weekly phone calls, alarmreminders, SMS, home visits, extra visits to the study center, support group, adjustment of ART drug doses, adjustment of non-ART drugs 6

  7. Viral load and genotypic testing Viral load monitoring : • Every 3-months • PROSPECTIVE, RESULTS PROVIDED IN REAL-TIME TO CLINICIANS • Month-3 resultused to inform Month-4 decision • Month-7, 10, 13 results : switch to 3rd-line at any time duringfollow-up if confirmed VL >1000 copies/ml Genotypicresistancetesting: • Plasma samplefrozen at Day-0 and Month-16 • Genotypictesting for all D-0 and M-16 sampleswith VL > 400 copies/ml • RETROSPECTIVE, RESULTS NOT AVAILABLE IN REAL-TIME TO CLINICIANS • Genotypictesting for all sampleswith VL > 400 copies/ml 7

  8. Definitions - Genotypic Sensitivity Score (GSS) • Number of drugs in ongoing regimen to which the patient’s virus has genotypic sensitivity - Month-4 decision appropriateness • Decision taken at Month-4 retrospectively judged on the basis of genotypes at Day-0 : - Inappropriate absence of switch: resistance to PI or GSS<2 - Inappropriate switch: sensitivity to PI and GSS=3 - Resistance accumulations • New resistance mutations occuring between Day-0 and Month-16 in patients with viral load >400 copies at Day-0 and Month-16 8

  9. Baseline characteristics, N=198 * The NRTIs were TDF-XTC in 52% of patients 9

  10. Month-4 decision Inclusion Month-4 decision Continue 2nd-line: N=130 (66%) 2nd-line • Death, 5 (2.5%) Switch to 3rd-line: N=63 (32%) 10

  11. Month-16 outcomes Inclusion Month-4 decision Month-16 outcomes Continue 2nd-line: N=130 (66%) • Overall, n (%) • Death: 15 (8%) • LTFU: 4 (2%) • VL <50 cp/ml: 101 (51%) • 50-400 cp/ml: 46 (23%) • >400 cp/ml:31 (17%) 2nd-line Switch to 3rd-line: N=63 (32%) 11

  12. Month-16 outcomes, by Month-4 decision Inclusion Month-4 decision Month-16 outcomes Continue 2nd-line: N=130 • Death: 6 (5%) • LTFU: 4 (3%) • VL <50 cp/ml:64 (49%) 50-400 cp/ml: 39 (30%) >400 cp/ml:17 (13%) 2nd-line • Death, 5 (2.5%) • Death: 4 (6%) • LTFU: 0 (0%) • VL <50 cp/ml:37 (59%) 50-400 cp/ml: 7 (11%) >400 cp/ml:14 (22%) Switch to 3rd-line: N=63 12

  13. Probability of first VL<50 over time, by Month-4 decision 82% 77% 13

  14. Other secondary endpoints, by Month-4 decision * 11 NRTI, 12 NNRTI, 8 PI ** 3 NRTI, 8 NNRTI, 5 PI, 0 RAL 14

  15. Discussion • In settings where viral load is routinely used for monitoring but routine genotypic testing is not available for real time use : • An intense adherence reinforcement phase, used as a tool to distinguish between patients who can still benefit from their current regimen and those who truly need third-line ART allowed to take appropriate decision of switching/ not switching in most patients • Resistance accumulation was rare • Third-line ART was well tolerated • Accessibility to viral load monitoring, to adherence reinforcement measures, and to third-line drugs should be reinforced 15

  16. Acknowlegments ANRS research site in Côte d’Ivoire • All patients who accepted to participate in the study Coordinating Investigators: R. Landman, Paris, France; SP. Eholié, Abidjan, Cote d’ivoire • ANRS: JF . Delfraissy, B. Bazin, G. Colin, P. Garcia • IMEA: PM. Girard, A. Benalycherif, B. Gadaleta • INSERM 1219/PACCI: X. Anglaret, J. Lecarrou, D. Gabillard, S. Karcher, L. N’Guessan, C. Nchot, E. Amani, A. Kouakou, R. Konan • GIP ESTHER: G. Raguin, C. Michon, A. Laurent, JM. Masumboko, A. Beugny • Trainer Forma Santé : C. Pinosa, N. Bernard, AM. Ane • Adherence group: C. Danel, C. Michon, L. Slama, A. Sawadago, R. Tubiana • SMIT Abidjan: E. Bissagnéné, F. Ello, F. Eboumou, Z. Diallo, Y. Siloué, F. Kouakou, J. Dano , M. Abanou • CePreF Abidjan: E. Messou, A. Anzian, P. Gouessé, J. Goli, A. Tchéhy, MC. Kassi • Day care Unit Bobo-Dioulasso: A. Sawadogo, L. Slama , J. Zoungrana, I. Soré, J.R. Traoré, G. Bado • CRCF Dakar and SMIT Dakar: M. Seydi, G. Laborde, M. Maynart, N. Gaye, M. Diallo, M. Basty • Cedres Abidjan: H. Menan, A. Emieme • Virology Unit (Necker et St Louis, Paris, Dakar): ML. Chaix, C. Rouzioux, C. Toure-Cane • Mali team: D. Minta, L. Tubiana, M. Fomba, A. Maiga, O. Dogoni, K. Kassogué, M. Cissé • Ouagadougou team: J. Drabo, I. Diallo, M. Congo • Scientific Advisory Board: PM. Girard (Chairman), E. Bissagnéné, B. Bazin, X. Anglaret, A. Desclaux, G. Raguin, C. Michon, C. Katlama, Y. Yazdapanah, E. Bissagnéné, R. Tubiana, E. Ouattara, ML. Chaix, AG. Marcellin, C. Touré-Kane, D. Minta, M. Seydi, AM. Maiga, G. Peytavin, Y. Coulibaly, A. Kambou-Sawadogo, I. Ba, A. Sangho, L. Slama 16

More Related